DiaSorin, Inc., has received Food and Drug Administration (FDA) clearance for its LIAISON Aldosterone immunoassay. The assay, which uses chemiluminescent immunoassay technology, is intended for the quantitative determination of aldosterone in human serum, EDTA plasma, and urine samples.
Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex. Its function is to increase sodium reabsorption in the kidneys. The test is primarily used for the diagnosis of hypertension, the primary cause of many cardiac ischemic and cerebral events.
The addition of the new aldosterone assay to the LIAISON analyzer menu, and its combination with the Direct Renin assay, enable DiaSorin to provide the complete hypertension panel. More than 4700 LIAISON systems are in use worldwide with a menu of 100 diagnostic tests including endocrinology, bone and mineral, infectious disease, autoimmune, and hepatitis assays.
DiaSorin, headquartered in Saluggia, Italy, employs more than 1,500 employees worldwide. The company’s U.S. operations are located in Stillwater, Minnesota. Learn more about products, including immunodiagnostic solutions, provided by DiaSorin.
